|
WO2020190971A1
|
|
Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
|
|
EP3478664A1
|
|
Methods for the synthesis of deuterated dextromethorphan
|
|
US2016143901A1
|
|
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
|
|
US2019111047A1
|
|
Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
|
|
AU2015203262A1
|
|
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders D2
|
|
AU2013202187A1
|
|
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders - D1
|
|
US2011212987A1
|
|
Method of reducing cns and gastrointestinal side affects associated with long-term dextromethorphan/low-dose quinidine combination therapy
|
|
WO2005081749A2
|
|
Neutralizing human antibodies to anthraxtoxin
|
|
AU2004200969A1
|
|
Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
|
|
TW200403997A
|
|
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
|
